Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer).
Estimates of the social cost of carbon vary widely as a function of different ethical parameters. Faced with values ranging from US$10 to US$1,000 per tCO2 and above, some perplexed policymakers have adopted 'target-consistent' carbon pricing instead.
Should human genome editing be limited to somatic cells, or should germline genome editing also be permitted? Should (apparently) permissible human genome editing be limited to therapeutic purposes, or should enhancement purposes also be permitted? Who decides, and on what basis?